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Dialysate magnesium level and blood pressure.
Background. We investigated the way dialysate magnesium
(dMg) concentrations could affect blood pressure (BP) during
hemodialysis (HD).
Methods. Eight HD patients underwent four midweek HD
treatments consecutively, using, during each four-hour HD ses-
sion, one of the following four dialysate formulations, in ran-
domized order, which differed only with regard to dMg and
dialysate calcium (dCa) concentrations (in mmol/L): 0.75 dMg,
1.75 dCa (group I); 0.25 dMg, 1.75 dCa (group II); 0.75 dMg,
1.25 dCa (group III); 0.25 dMg, 1.25 dCa (group IV). Before
HD and at four 60-minute intervals during the HD sessions,
BP and noninvasive measurements of cardiac index (CI) were
obtained. Additionally, 14 HD patients were treated for four
weeks with 0.5 mmol/L dMg, followed by four weeks with
0.25 mmol/L dMg, and another four weeks with 0.75 mmol/L
dMg, in random order. In all treatments dCa was 1.25 mmol/L.
BP and symptoms were recorded during each HD session.
Results. Mean arterial pressure (MAP) decreased to a sig-
nificantly (P < 0.05) greater extent in group IV compared to
the other groups. This substantial drop in MAP by 15.2% in
group IV, paralleled by a 12.1% and 17% drop in CI and stroke
index, respectively, was not seen in group II, despite compara-
ble reductions in intradialytic serum Mg (sMg) of about 35%
in both groups. In groups I and III, the increase in sMg by 2%
did not compromise BP via vasodilatation. In the second study,
treatment with 0.75 mmol/L dMg was superior to the other two
treatments regarding intradialytic morbidity (P < 0.001) and
BP stability (P < 0.05).
Conclusion. We (1) identified a dialysis solution containing
0.25 mmol/L Mg and 1.25 mmol/L Ca as a major cause of intra-
dialytic hypotension (IDH) due to an impairment of myocar-
dial contractility, and (2) showed that increasing dMg level to
0.75 mmol/L could prevent IDH frequently seen with the use
of 1.25 mmol/L dCa. Thus, manipulating dMg levels indepen-
dently or in concert with dCa levels might have important
implications with regard to dialysis tolerance.
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Despite numerous advances in hemodialysis (HD)
technology in recent years, intradialytic hypotension
(IDH) continues to be a problem with considerable mor-
bidity, occurring in up to 20% of HD treatments. The eti-
ology of IDH is probably multifactorial [1], and therefore,
many specific prevention and treatment approaches have
been proposed to reduce the incidence of IDH. Manipu-
lating the dialysate composition, mainly sodium and cal-
cium (Ca) concentrations [2–4], is among those of proven
efficacy. There are reasons to believe that dialysate mag-
nesium (dMg) levels may also influence intradialytic
blood pressure (BP). Mg exerts a direct modulatory ac-
tion on cardiac excitability and vascular smooth mus-
cle contraction and relaxation [5–6]. Hypomagnesemia
has been shown to contribute significantly to cardiac
morbidity and mortality, particularly in states associated
with myocardial ischemia [7]. Magnesium therapy, both
for deficiency replacement and in higher pharmacologic
doses, has been beneficial in improving cardiovascular
hemodynamics and electrophysiologic functioning. In ad-
dition, the vasodilatory effects of the increased serum Mg
(sMg) are demonstrated by the BP-lowering effect via a
fall in systemic vascular resistance of acute Mg admin-
istration in preeclampsia [8]. However, the role of sMg
as a potential modulator of the cardiovascular response
during HD has not been studied systematically.
sMg increases in advanced renal failure, and in pa-
tients on regular HD treatment Mg status mainly
depends upon the concentration of dMg. To avoid the
development of HD-related hypermagnesemia, poten-
tially induced by high dMg of ≥0.75 mmol/L, low dMg
concentrations of 0.25 to 0.5 mmol/L are commonly used
today. Current practice utilizes a dCa of 1.25 mmol/L to
minimize the risk of HD-induced hypercalcemia caused
by high doses of calcium salts and vitamin D given for
secondary hyperparathyroidism treatment, along with its
related morbidity. However, the use of 1.25 mmol/L dCa
has been associated with significant decreases of BP dur-
ing HD compared to 1.75 mmol/L dCa. Given these
considerations, awareness of the way sMg can influence
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cardiovascular status during HD, particularly with low
dCa of 1.25 mmol/L, would be of paramount clinical im-
portance. In the event that intradialytic hypomagnesemia
induced by a low dMg of 0.25 mmol/L demonstrates ad-
verse cardiovascular effects, as recent bibliographic data
[9] suggest, then a low dMg of 0.25 mmol/L in the pres-
ence of a low dCa of 1.25 mmol/L may put HD pa-
tients at a higher risk of developing IDH. On the other
hand, the possibility exists that the use of a high dMg of
0.75 mmol/L, by avoiding hypomagnesemia or even caus-
ing a slight degree of hypermagnesemia, may exert a
positive effect on systemic hemodynamics, capable of
partially or completely counteracting the adverse hemo-
dynamic effects elicited with a 1.25 mmol/L dCa, and,
consequently, improving HD tolerance.
The aim of the present study was to investigate the
effect of dMg modulations on intradialytic hypotension,
and to make therapeutic recommendations on the use of
dMg level. For this purpose, we examined noninvasively
the acute hemodynamic effects of changes in sMg in con-
junction with those of ionized serum Ca (iCa) during HD,
using different combinations of Ca and Mg concentra-
tions in the dialysate. We chose this model because Mg
regulates the activity of vascular smooth muscle cells by
competing with Ca [6], and iCa does not remain constant
during HD. The objectives of the present study were to
identify those dialysate formulations, with respect to Mg
and Ca levels, exerting the most or less favorable effects
on systemic hemodynamics during HD, and determine
the optimal dMg level that could protect against IDH
induced by a low dCa of 1.25 mmol/L [10–11].
METHODS
Study A
Eight HD patients, five men and three women, 61 ±
14 years old, were studied. Their mean time on HD was
44 ± 32 months. All patients had uncompromised left sys-
tolic function (ejection fraction>40%), no clinical history
suggestive of ischemic cardiac disease, no wall motion
abnormalities and valve heart disease, based on echocar-
diographic examination, and normal sinus rhythm. They
were clinically and hemodynamically stable, with a hema-
tocrit ranging between 33% and 38%, and a ultrafiltra-
tion rate (UF) per treatment equal or less than 3% of
their “dry” (or euvolemic) weight, estimated by clinical
criteria. The etiology of renal failure was hypertensive
nephrosclerosis (N = 3), interstitial nephritis (N = 3),
glomerulonephritis (N = 1), and undetermined (N = 1).
The composition of the dialysate was Na 140 mmol/L,
K 2 mmol/L, Ca 1.75 mmol/L, Mg 0.5 mmol/L, bicarbon-
ate 35 mmol/L, acetate 3 mmol/L, and Cl 109.5 mmol/L.
None of the dialysis patients were on antihypertensive or
other vasoactive drugs during the study period. All pa-
tients gave informed consent to participate in the study,
which had been approved by the institutional board of
General Hospital of Chios.
Study design
All patients underwent four midweek HD treatments
consecutively, using, during each HD session, one of the
following four dialysate formulations, which differed only
with regard to dialysate Mg (dMg) and Ca (dCa) concen-
trations: dMg 0.75 mmol/L, dCa 1.75 mmol/L (group I);
dMg 0.25 mmol/L, dCa 1.75 mmol/L (group II); dMg 0.75
mmol/L, dCa 1.25 mmol/L (group III); dMg 0.25 mmol/L,
dCa 1.25 mmol/L (group IV). Between the four interven-
tion studies, patients were treated with their routine dial-
ysis prescription, as described above. The order in which
each patient was treated with the four-dialysate formu-
lation was randomly assigned. Only the technician of the
dialysis department knew the concentration of Mg and Ca
in the dialysate used for each treatment. Dialysis was per-
formed on a volumetric-controlled UF dialysis machine
(Gambro AK; Gambro, Lund, Sweden), using polysul-
fone (Fresenius, Bad Homburg, Germany) low-flux dia-
lyzers (F7HPS, 1.6 m2). Blood flow was 300 mL/min and
dialysate flow was 500 mL/min. The dialysate tempera-
ture was 37◦C and the dialysate Na concentration was
140 mmol/L. During each of the four intervention treat-
ments, the biochemical and hemodynamic parameters de-
scribed next were measured.
Biochemical parameters
Arterial blood samples were drawn for biochemical pa-
rameters determination before the initiation and imme-
diately after the completion of HD treatment. Sodium
(Na), potassium (K), chloride (Cl), iCa, pH, and pCO2
were measured with the use of a Stat Profile analyzer
(Nova Biomedical, Waltham, MA, USA). Serum bicar-
bonate concentration was calculated from the pH and
pCO2 using the Henderson-Hasselbach equation and pK
of 6.1. Total serum calcium (sCa), phosphorus (P), albu-
mins, blood urea nitrogen (BUN), and creatinine were
analyzed by usual laboratory methods. A Nova 8 ana-
lyzer was used to measure serum ionized Mg (iMg). sMg
was measured with a colorimetric method (Cobas Inte-
gra System, Roche Diagnostics, Mannheim, Germany),
and parathyroid hormone (PTH) was measured using an
immunoradiometric assay.
Hemodynamic parameters
Each one of the following hemodynamic parameters
was measured before dialysis, and at one-hour intervals
during the subsequent four-hour dialysis period. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were measured with an automatic blood pressure de-
vice (Datex-Ohmeda, Instrumentarium Comp, Helsinki,
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Finland), and mean arterial pressure (MAP) was com-
puted as the DBP plus the 1/3 of the pulse pressure.
The mean of three consecutive measurements was cal-
culated. Cardiac index (CI), the cardiac output (CO) in-
dexed by body surface area, and heart rate (HR), were
derived from thoracic electric bioimpedance (TEB) data,
obtained with the NCCOM3-R7/CDDP system manu-
factured by CardioDynamics International Corp. (Irvine,
CA, USA). The validity, limitations, and the reproducibil-
ity of the TEB to measure CO have been described by
others [12–14]. TEB has been validated [15] and exten-
sively employed for monitoring systemic hemodynamics
during hemodialysis [16–17]. Total peripheral resistance
(TPR) index (TPRI) was calculated as TPRI = 80 ×
MAP/CI, where 80 is a conversion factor.
Study B
In this study, we tried to identify the optimal dMg level
that could ameliorate or even abolish BP fall, frequently
seen upon using a low dCa concentration of 1.25 mmol/L,
an effective means to prevent or treat HD-related hyper-
calcemia. Fourteen HD patients, 10 men and four women,
with a mean age of 62.3 ± 12.4 years and a mean time on
HD of 55 ± 53 months, participated in the study. All pa-
tients were normotensive (BP <140/90) within the last
three months, and none of them was on antihypertensive
treatment during the study period. IDH, defined as a de-
crease in blood pressure necessitating fluid replacement
therapy, was documented in less than 15% of their regu-
lar HD sessions for the three months prior to study par-
ticipation. Patients’ mean interdialytic weight gain was
between 1.5 and 2.5 kg, and urine output was less than
300 mL/day. Exclusion criteria were a history of prior
myocardial infarction or cardiovascular intervention,
symptomatic coronary heart disease, a compromised left
ventricular function (ejection fraction 40% or less), a
predialysis SBP less than 115 mm Hg, cardiac arrhyth-
mias, and diabetes mellitus. The cause of renal failure was
hypertensive nephrosclerosis (N = 3), interstitial nephri-
tis (N = 3), polycystic kidney disease (N = 2), glomeru-
lonephritis (N = 2), retroperitoneal fibrosis (N = 1), and
undetermined (N = 3). All patients were treated with
vitamin D and CaCO3 supplements for presumed os-
teitis fibrosa (PTH >400 pg/mL) and were maintained
on 1.25 mmol/L dCa and 0.50 mmol/L dMg for more
than six months prior to the study. First, each patient un-
derwent a four-week treatment with a medium dialysate
Mg of 0.5 mmol/L (MdMg group). After the completion
of this four-week HD treatment, all patients were dia-
lyzed, in randomized order, for four weeks with a low
dMg of 0.25 mmol/L (LdMg group), and another four
weeks with a high dMg of 0.75 mmol/L (HdMg group),
separated by an interval of a two-week period, during
which MdMg treatment was utilized. In all dialysate for-
mulations, Ca concentration was 1.25 mmol/L and the
concentrations of all other ions were the same as in study
A. BP and HR were measured before dialysis and ev-
ery hour during the four-hour dialysis period, and in-
trasession events were recorded in each treatment. The
latter included symptomatic and asymptomatic hypoten-
sion. Symptomatic hypotension was defined as the re-
quirement of volume expansion therapy due to either a
decrease in SBP of more than 40 mm Hg below the pre-
dialysis SBP, a decrease in SBP below 95 mm Hg, or a
decrease in blood pressure accompanied by symptoms
requiring intervention. Asymptomatic hypotension was
defined as a SBP of less than 90 mm Hg without symp-
toms. Intradialytic symptoms were recorded by the nurs-
ing staff, who were blinded to the dMg and dCa. As in
study A, only the technician of the dialysis department
knew dMg and dCa concentrations used for each treat-
ment. During the second midweek dialysis session of the
last three weeks, blood samples were drawn just before
the start and immediately after the completion of the HD
treatment for sMg and iCa measurement. All dialyses
were performed with bicarbonate as a buffer base and
with low-flux polysulfone dialyzers (F7HPS, 1.6 m2 and
F8HPS, 1.8 m2). The rest of dialysis parameters in study
B were the same as in study A.
Statistical analysis
Statistical analysis was performed using SPSS/PC 8.0
microcomputer statistical software package (Chicago, IL,
USA). Biochemical pre-HD values were compared be-
tween groups by using analysis of variance (ANOVA).
Within groups, pre- to post-HD changes were evaluated
using Student t test for paired data. For the analysis of the
hemodynamic data, as there were multiple time points for
each of the four treatments, a two-factor (time × treat-
ment) repeated measures ANOVA design was used.
In analyzing blood pressure data from study B, a two-
factor repeated measures ANOVA design was used as
above, except that the blood pressures from 12 sessions
were averaged first at each time point prior to analysis.
Data were pretested for period and carryover effects dur-
ing the crossover phase of the study. There was no evi-
dence of period or carryover effect (all P > 0.396) of
any treatment on sMg, iCa, and blood pressure measure-
ments. Results were similar with and without carryover in
the model. For analysis of symptoms, each dialysis session
was scored as 0 or 1 for each symptom. We used Cochran’s
Q statistic to test for differences in symptoms between
treatments. For two group comparisons, McNemar test
was used instead. Parameters are expressed as absolute
values or as percentage changes from baseline. Values
are expressed as mean ± SD, unless otherwise stated.
The 95% level confidence interval (CI) for the mean is
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Table 1. Pre-HD and post-HD data of biochemical parameters and body weight in treatment groups I, II, III, and IV of study A
Group I Group II Group III Group IV
Parameter Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD
sMg mmol/L 1.01 ± 0.20 1.01 ± 0.11 1.04 ± 0.18 0.66 ± 0.09b 1.05 ± 0.15 1.05 ± 0.11 1.05 ± 0.15 0.69 ± 0.09b
iMg mmol/L 0.71 ± 0.18 0.70 ± 0.13 0.74 ± 0.13 0.47 ± 0.09b 0.71 ± 0.12 0.71 ± 0.10 0.72 ± 0.10 0.47 ± 0.06b
iMg/sMg 0.70 ± 0.06 0.68 ± 0.06 0.71 ± 0.04 0.72 ± 0.09 0.68 ± 0.06 0.69 ± 0.06 0.69 ± 0.06 0.68 ± 0.09
sCa mmol/L 2.53 ± 0.40 2.67 ± 0.32a 2.50 ± 0.39 2.65 ± 0.31a 2.48 ± 0.40 2.32 ± 0.19a 2.51 ± 0.42 2.28 ± 0.18a
iCa mmol/L 1.22 ± 0.15 1.29 ± 0.10a 1.22 ± 0.17 1.28 ± 0.08a 1.22 ± 0.15 1.14 ± 0.09a 1.21 ± 0.15 1.11 ± 0. 08a
iCa/sCa 0.49 ± 0.02 0.49 ± 0.04 0.49 ± 0.03 0.48 ± 0.03 0.50 ± 0.03 0.49 ± 0.03 0.49 ± 0.02 0.49 ± 0.04
PTH pg/mL 237 ± 262 185 ± 256 234 ± 168 182 ± 160 211 ± 148 292 ± 207a 248 ± 255 331 ± 357a
pH 7.41 ± 0.02 7.47 ± 0.03b 7.40 ± 0.02 7.47 ± 0.03b 7.41 ± 0.03 7.47 ± 0.03b 7.40 ± 0.03 7.48 ± 0.02b
PCO2 mm Hg 33.9 ± 3.13 35.1 ± 2.58 34.9 ± 4.56 35.7 ± 3.57 35.3 ± 3.64 36.4 ± 3.69 34.8 ± 3.64 36.6 ± 3.69
HCO3 mmol/L 21.8 ± 2.31 25.9 ± 1.64b 22.1 ± 2.8 26.1 ± 2.79b 22.7 ± 2.0 26.8 ± 2.41b 21.8 ± 2.77 27.3 ± 2.75b
Na mmol/L 141 ± 2.21 140 ± 1.75 141 ± 3.73 142 ± 1.6 141 ± 1.96 142 ± 0.83 140 ± 2.73 142 ± 1.98
K mmol/L 4.65 ± 1.17 3.51 ± 0.49b 4.68 ± 1.07 3.53 ± 0.4h 4.72 ± 0.63 3.55 ± 0.40b 4.74 ± 0.85 3.55 ± 0.36b
Cl mmol/L 103 ± 2.33 100 ± 1.64b 102 ± 0.92 100 ± 1.85a 103 ± 1.41 101 ± 1.77a 103 ± 1.89 101 ± 1.28a
BUN mmol/L 80.8 ± 9.2 28.5 ± 5.1b 79.5 ± 10.5 26.8 ± 5.4b 78.3 ± 8.5 26.9 ± 3.3b 79.0 ± 7.2 26.6 ± 4.0b
Cr mmol/L 856 ± 185 375 ± 102b 847 ± 214 392 ± 135b 839 ± 183 371 ± 89b 827 ± 243 382 ± 128b
Albumin g/dL 4.01 ± 0.29 4.09 ± 0.31 4.04 ± 0.32 4.18 ± 0.45 3.99 ± 0.34 4.15 ± 0.35 3.98 ± 0.25 4.11 ± 0.43
P mmol/L 1.82 ± 0.44 0.8 ± 0.2b 1.84 ± 0.42 0.88 ± 0.22b 1.83 ± 0.45 0.84 ± 0.25b 1.82 ± 0.33 0.84 ± 1.02b
BW kg 61.1 ± 9.92 59.3 ± 9.81a 60.9 ± 9.52 59.3 ± 9.79a 61.4 ± 9.52 59.6 ± 9.86a 60.9 ± 9.76 59.5 ± 9.87a
Abbreviations are: sMg, total serum magnesium; iMg, ionized serum magnesium; sCa, total serum calcium; iCa, ionized serum calcium; PTH, parathormone; Na,
sodium; K, potassium; Cl, chloride; BUN, blood urea nitrogen; Cr, creatinine; P, phosphorus; BW, body weight. Data are expressed as mean ± SD.
aP < 0.05 vs. pre-HD; bP < 0.001 vs. pre-HD.
also given, where appropriate. Changes were considered
statistically significant for P less than 0.05 (two-sided).
RESULTS
Study A
sMg, iMg, sCa, iCa, and PTH were similar prior to
the treatments (Table 1). sMg increased slightly by 2.1%
(95% CI −5.9 to 10.2) and 2.03% (95% CI −3.6 to 7.6)
in the 0.75 mmol/L dMg groups I and III at the end of
HD, and decreased significantly (P < 0.001) with the use
of a 0.25 mmol/L dMg in groups II and IV by 35.6%
(95% CI −40.2 to −30.9) and 34.2% (95% CI −38.1
to −30.2), respectively. In treatment groups I and III,
sMg increased in four of eight patients, but decreased in
the other patients. Almost identical intradialytic changes
were observed regarding iMg. Both before and after HD,
the correlation between iMg and sMg (total serum Mg)
was high (r = 0.93; P < 0.01 and r = 0.92; P < 0.01,
respectively). In the light of this highly significant corre-
lation between iMg and sMg, we opted to refer only to
sMg in the text, since the latter is more widely used in
clinical practice and reported in literature. iCa increased
(P < 0.05) with 1.75 mmol/L dCa in treatment groups
I and II by 6.1% (95% CI 0.9 to 11.4) and 6.1% (95%
CI 0.6 to 11.5), and decreased (P < 0.05) in groups III
and IV by 6.4% (95% CI −11.4 to −1.5) and 7.7% (95%
CI −13.6 to –1.8), respectively, where the dCa level was
1.25 mmol/L. The correlation between changes in iCa and
sCa was high (r = 0,90; P < 0.01). PTH decreased equally
by 23.3% (95% CI−54.7 to 7.9) and 22.3% (95% CI−71.2
to 26.6) during HD in groups I and II and increased (P <
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Fig. 1. Percent changes in serum magnesium (sMg), ionized serum
calcium (iCa), and serum parathormone (PTH) in the four treatment
groups during hemodialysis. ∗P < 0.05; ∗∗P < 0.001.
0.05) by 43.5% (95% CI 10.3 to 76.7) and 46.8% (95%
CI 10.3 to 83.3) in groups III and IV, respectively. The
changes in PTH (suppression or stimulation) were very
closely related to changes in iCa (Fig. 1). The predialy-
sis values as well as the intradialytic changes of all other
biochemical parameters measured did not differ in the
four treatment groups (Table 1). A significant decrease
in serum K, Cl, P, BUN, and creatinine, and a significant
increase in pH and HCO3 were seen during HD, whereas
PCO2, serum Na, and albumins remained unchanged. In-
tradialytic changes in iMg were correlated among all lab-
oratory parameters measured only to those of sMg (r =
0.75; P < 0.05). Finally, intradialytic fluid removal was
similar between treatments groups (Table 1).
Hemodynamic indices were similar prior to the treat-
ments (Table 2). As shown in Figure 2, BP decreased to
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Table 2. Baseline (predialysis) hemodynamic data in groups I, II, III,
and IV of study A (N = 8) and in the high (0.75 mmol/L) dialysate
magnesium (HdMg) group, medium (0.5 mmol/L) dialysate
magnesium (MdMg) group, and low (0.25 mmol/L) dialysate
magnesium (LdMg) group of study B (N = 14)
Study A
Parameter Group I Group II Group III Group IV
SBP mm Hg 135.8 ± 13.6 133.6 ± 21.3 132.9 ± 28.3 135.0 ± 19.7
DBP mm Hg 69.4 ± 10.5 69.6 ± 11.5 66.6 ± 11.8 68.0 ± 7.0
MAP mm Hg 91.5 ± 13.8 91.0 ± 12.9 88.7 ± 15.8 90.3 ± 7.6
CI L/min/m2 3.55 ± 1.24 3.37 ± 1.30 3.39 ± 0.95 3.43 ± 1.09
SI mL/m2 44.3 ± 15.7 41.9 ± 16.4 43.6 ± 15.5 45.7 ± 18.2
HR bpm 81.3 ± 13.8 83.0 ± 20.3 80.0 ± 13.9 78.1 ± 13.9
TPRI dyn.sec/ 2275 ± 836 2417 ± 958 2218 ± 719 2313 ± 806
cm5/m2
Parameter Study B
(Average of
12 sessions) HdMg MdMg LdMg
SBP mm Hg 130.0 ± 9.3 129.1 ± 9.6 129.5 ± 10.6
DBP mm Hg 76.2 ± 10.3 76.0 ± 9.2 75.7 ± 9.2
MAP mm Hg 94.1 ± 9.3 93.8 ± 8.8 93.6 ± 8.7
HR bpm 79.2 ± 10.7 78.7 ± 11 79.5 ± 11
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial pressure; CI, cardiac index; SI, stroke index; HR, heart
rate; bpm, beats per minute; TPRI, total peripheral resistance index. Data are
expressed as mean ± SD.
a greater extent in group IV compared to the other three
groups, in which BP fell similarly. MAP, averaged across
time, decreased by 15.2% (95%CI −19.8 to −10.7) in
treatment group IV, whereas it dropped by 6.3% (95% CI
−12 to – 0.6), 4.2% (95% CI −9 to 0.6), and 6.2% (95% CI
−12.9 to 0.5) in the groups I, II, and III, respectively. The
intrasession changes of both SBP and DBP were analo-
gous to MAP. The treatment effect (P < 0.05) and the
time effect (P < 0.001) for SBP, DBP, and MAP were sta-
tistically significant. There was also a time × treatment
interaction effect for SBP (P < 0.01) and MAP (P < 0.05),
but not for DBP. Conceptually, the interaction term can
be considered as a test to show whether or not two or more
factors relate with each other. Accordingly, the presence
of a time × treatment interaction effect for SBP, and
MAP suggested that the effect of treatment depended
on time. This interaction (or relationship) between time
and treatment is depicted in Figure 2, where SBP and
MAP decreased significantly to a much greater extent in
treatment group IV than in the other groups during the
second half of HD. On the contrary, changes (decrease) in
DBP did not differ significantly among the four treatment
groups across time periods during HD, findings implying
the absence of an interaction between time and treat-
ment. The profile of CI and stroke index (SI) changes
was similar to that of MAP (Fig. 2). Both mean CI and SI
reductions over time by 12.1% (95% CI −21.6 to −2.6)
and 17% (95% CI −28.4 to –5.7), respectively, in group
IV, were significantly greater from that in group I and
III, but not from that in group II. The treatment effect
(P < 0.05) and the time × treatment effect for CI (P <
0.05) and SI (P < 0.001) were statistically significant, and
a time effect for CI (P < 0.01) was present only in treat-
ment group IV. Given that TPRI remained unchanged in
group IV, it is apparent that the blood pressure effect in
that group was primarily due to changes in cardiac out-
put through analogous changes in stroke volume. Overall,
intradialytic TPRI alterations were less pronounced than
the corresponding CI alterations. TPRI did not increase
in any group. The maximum reduction in TPRI, averaged
across time, observed in group III (5.4%; 95% CI −12.9
to 2.1) differed significantly (P < 0.05) from the mini-
mum one seen in group II (0.13%; 95% CI −10.2 to 9.9),
but the treatment effect was not statistically significant.
Finally, there was not a treatment effect for HR, which
increased significantly (P < 0.05) with time in groups II,
III, and IV by 5.3% (95% CI 0.2 to 10.3), 4.5% (95% CI
−1.4 to 10.4), 6% (95% CI −2.4 to 14.5), respectively, but
not in group I (3.3%; 95% CI 0 to 6.6).
Study B
The mean pre- and post-HD sMg and iCa levels, as well
as body weights, in the three treatment groups are pre-
sented in Table 3. The mean pre-HD sMg level (1.21 ±
0.12 mmol/L, range 0.99 to 1.37) in the HdMg group was
significantly higher (P < 0.001) than that seen in both
MdMg (1.06 ± 0.11 mmol/L, range 0.88 to 1.28) and LdMg
(0.91 ± 0.13 mmol/L, range 0.7 to 1.07) groups. Hyper-
magnesemia (sMg >1.1 mmol/L) was observed in nine
(64%) and five (36%) out of 14 patients in the HdMg
and MdMg groups, respectively, while it was absent in
the LdMg group. sMg decreased by 0.1% (95% CI −4.1
to 3.9), 12.9% (95% CI −15.8 to −10) and 26.1% (95%
CI −29.9 to −22.3) during HD in the HdMg, MdMg, and
LdMg groups, respectively. Mean pre-HD iCa levels did
not differ among the treatment groups, and the iCa lev-
els decreased (P < 0.01) equally about 3% (95% CI −5
to −1) with all treatments. Mean (four-week) pre-HD
weights and the mean fluid loss during HD were compa-
rable in the three treatment groups.
Mean predialysis BP and HR did not differ among
treatment groups (Table 2). The treatment effect was sig-
nificant for SBP (P < 0.05), DBP (P < 0.05), and MAP
(P < 0.05), and there was a time × treatment interaction
effect for DBP (P < 0.05) and MAP (P < 0.05). SBP, DBP,
and MAP decreased significantly (P < 0.001) with time in
all treatment groups. There was no treatment or time ×
treatment interaction effect for HR. According to anal-
ysis across time points, depicted in Figure 3, intradialytic
SBP decreased significantly (P < 0.05) with both LdMg
and MdMg treatments compared to HdMg treatment.
DBP fell significantly with LdMg treatment compared to
MdMg (P < 0.05) and HdMg (P < 0.01) treatments. Fi-
nally, MAP fell to a greater extent (P < 0.01) with LdMg
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Fig. 2. Hourly intradialytic percent changes in (A) systolic blood pressure (SBP), (B) diastolic blood pressure (DBP), (C) mean arterial pressure
(MAP), (D) cardiac index (CI), (E) stroke index (SI), and (F) total peripheral resistance index (TPRI). () Group I, () group II, (•) group III,
(◦) group IV. †Significant difference between group IV and group I. ∗Significant difference between group IV and group II. ‡Significant difference
between group IV and group III. ∗∗Significant difference between group II and group III. Data points represent mean values ± SEM. Study A,
N = 8.
Table 3. Pre-HD and post-HD data of biochemical parameters and body weight in the high (0.75 mmol/L) dialysate magnesium (HdMg) group,
medium (0.5 mmol/L) dialysate magnesium (MdMg) group, and low (0.25 mmol/L) dialysate magnesium (LdMg) group of study B
HdMg MdMg LdMg
Parameter Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD
iCa mmol/L 1.17 ± 0.06 1.13 ± 0.03a 1.18 ± 0.08 1.14 ± 0.04a 1.16 ± 0.07 1.12 ± 0.04a
sMg mmol/L 1.21 ± 0.12c 1.20 ± 0.08 1.06 ± 0.11d 0.92 ± 0.09b 0.91 ± 0.13 0.67 ± 0.07b
BW kg 65.5 ± 12.3 63.4 ± 12.1b 65.6 ± 12.2 63.4 ± 12.1b 65.5 ± 12.2 63.6 ± 11.9b
Abbreviations can be found in Table 1. Data are expressed as mean ± SD.
aP < 0.01 vs. pre-HD; bP < 0.001 vs. pre-HD; cP < 0.001 vs. MdMg and LdMg; dP < 0.001 vs. LdMg.
than with HdMg treatment. Interestingly, the intradia-
lytic MAP drop by 8.1% (95% CI −10.7 to –5.5), 9.5%
(95% CI −12.2 to –6.7), and 10.7% (95% CI −13.2 to
−8.2) in the HdMg, MdMg, and LdMg, respectively, var-
ied with the sMg drop, described above, in the corre-
sponding groups. This positive correlation between the
magnitude of BP and sMg reduction observed further
emphasized the critical role of differentiated dMg con-
centration on the cardiovascular function.
Differences in intradialytic events between the three
treatment protocols are shown in Table 4. There were sig-
nificant (P < 0.05) differences in symptomatic hypoten-
sion among the three treatment groups. The percentage
of sessions with symptomatic hypotension in the HdMg
treatment group was significantly lower (4.2% vs. 10.7%)
than that in the LdMg treatment group. The correspond-
ing proportion of hypotensive sessions in the MdMg treat-
ment group was almost twice as higher than that in the
HdMg treatment group (7.7% vs. 4.2%). However, this
difference did not reach statistical significance. There
were fewer episodes of asymptomatic hypotension (P <
0.05) and total (symptomatic and asymtomatic) hypoten-
sion (P < 0.001) with HdMg as compared to both LdMg
and MdMg treatments.
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Fig. 3. Hourly intradialytic percent changes in (A) systolic blood pres-
sure (SBP), (B) diastolic blood pressure (DBP), and (C) mean arterial
pressure (MAP). () High (0.75 mmol/L) dialysate magnesium (HdMg),
(•) medium (0.5 mmol/L) dialysate magnesium (MdMg), () low (0.25
mmol/L) dialysate magnesium (LdMg). ∗Significant difference between
LdMg and HdMg groups. ∗∗Significant difference between LdMg and
both MdMg and HdMg groups. ‡Significant difference between HdMg
and both MdMg and LdMg groups. Data points represent mean values
± SD. Study B, N = 14.
DISCUSSION
Our results showed that intradialytic changes in sMg
played an important and independent role on systemic
hemodynamics only when HD was performed with a low
1.25 mmol/L dCa. No such role of sMg was apparent, or
even if present was not detected, during HD with a high
1.75 mmol/L dCa. Indeed, the most important findings of
the hemodynamic study were that a dialysate formulation
containing Mg and Ca concentrations of 0.25 mmol/L and
1.25 mmol/L, respectively, emerged as an important cause
of IDH, and during HD with 1.25 mmol/L dCa, BP was
preserved better with a high dMg of 0.75 mmol/L com-
pared to a low one of 0.25 mmol/L. Before we proceed to
the interpretation of these intriguing findings, resulting
from concomitant changes in sMg and iCa, it is appro-
priate to briefly state the available evidence regarding
the hemodynamic effects of changes in magnesemia and
calcemia individually.
Changes in iCa. Modest variations in iCa are cor-
related with clinically significant changes in myocardial
contractility. A number of recent investigations showed
a significant decrease of blood pressure during HD with
the use 1.25 mmol/L dCa as compared to 1.75 mmol/L
dCa, in both healthy [10, 17] and cardiac-compromised
HD patients [11]. Conversely, an intradialytic increase in
iCa, as it occurs with the use of high dCa concentrations,
results in a measurably higher intradialytic BP compared
to a dCa of 1.25 mmol/L due to an iCa-induced increase
in myocardial contractility [3–4], and thus, increasing the
dCa concentrations has been advocated as a means to
protect against intradialytic hypotension [11, 17].
Changes in sMg.
Hypomagnesemia. The majority of the in vitro experi-
ments in isolated ventricular tissue or myocytes record an
inverse relation between Mg concentration and inotropic
response, mediated probably by the antagonistic actions
between Mg and Ca [18–20]. Paradoxically, myocardial
contractility is usually compromised in animals on Mg-
deficient diet [21], or on perfusion of whole heart [22]
with low Mg (0.3 mmol/L) buffer. Mg deficiency–induced
coronary vasospasm [23], defective energy metabolism
[24], and excessive free radical generation [25] may be
important variables acting in concert or independently
to affect myocardial function. Despite the important role
of Mg deficiency or hypomagnesemia in the etiology of
cardiovascular pathology [9], the mechanisms by which
hypomagnesemia might lead to myocardial dysfunction
still remain unclear.
Hypermagnesemia. It has been systematically shown
that magnesium salt infusion lowers BP via a reduction
of TPR despite a moderate increase in cardiac output [8,
26–28]. The latter is accomplished via increases in HR
and coronary flow [27] or a direct myocardial effect [28–
29], independent of changes in preload, afterload, heart
rate, or flow [29]. These Mg-induced direct or indirect
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Table 4. Intradialytic symptoms, during 168 hemodialysis sessions, with high (0.75 mmol/L) dialysate magnesium (HdMg) treatment, low (0.25
mmol/L) dialysate magnesium (LdMg) treatment and medium (0.5 mmol/L) dialysate magnesium (MdMg) treatment
Treatment P value
HdMg LdMg MdMg HdMg vs. LdMg HdMg vs. MdMg LdMg vs. MdMg
Symptom N (%) N (%) N (%)
Symptomatic hypotension 7 (4.2) 18 (10.7) 13 (7.7) 0.019 >0.1 >0.1
Asymptomatic hypotension 11 (6.5) 26 (15.4) 24 (14.3) 0.009 0.026 >0.1
Total hypotension 18 (10.7) 44 (26.2) 37 (22.0) 0.001 0.004 >0.1
vasodilatory effects are dose dependent [27] and can be
elicited at plasma concentrations as low as 1.38 mmol/L
[28], while a concentration of 1.8 to 3.0 mmol/L has been
suggested for treatment of eclamptic convulsions [27].
According to our data, the substantial intradialytic fall
of BP seen with a HD solution containing Mg and Ca
concentrations of 0.25 mmol/L and 1.25 mmol/L, respec-
tively, was due to an unusual impairment of myocardial
contractility not compensated by an increased TPR. With
all other HD parameters standardized, this formulation
resulted in hypomagnesemia and hypocalcemia by de-
creasing sMg and iCa by 35% and by 7.7%, respectively,
situations shown to impact unfavorably on cardiac per-
formance. Thus, the combined cardiodepressant effects
of both hypomagnesemia and hypocalcemia was, most
probably, the basis for this unexpected myocardial dys-
function. Supported of this, the harmful effects on cardiac
function and BP detected with this HD formulation were
not seen with other formulations causing either only hy-
pomagnesemia (group II) or only hypocalcemia (group
III). Given that Mg is a naturally occurring calcium chan-
nel inhibitor, it is understandable that with a subnormal
level of Mg, the cardiovascular contractility increases or
decreases when the extracellular Ca is raised or lowered,
respectively.
Following fluid removal from the circulating blood vol-
ume by UF, refilling occurs from the extravascular com-
partment, which, by avoiding hypovolemia, serves as an
important compensatory mechanism to preserve BP sta-
bility. Plasma volume changes were not monitored in the
present study, so we cannot rule out inadequate vascu-
lar refilling as the cause of the cardiac output reduction
seen in the low dCa and dMg group of patients. However,
factors known to affect substantially plasma refilling rate,
including fluid overload, ultrafiltation rate, plasma albu-
min levels, dialysate sodium concentration, or dialysate
temperature were similar in all treatment groups, findings
that make this possibility unlikely.
In treatments that combine utilization of diffusion and
convection, there is a continuous interference between
these two transport mechanisms. Given the high-diffusive
coefficients of the ionized and complexed forms of Mg
and Ca in serum, convection transport has little influence
on the diffusive balance of Mg and Ca, respectively. In ad-
dition, the convective loss of the ultrafilterable blood Mg
and Ca, because it is limited to the weight loss in both low-
and high-flux HD, apparently contributes equally to the
overall Ca and Mg balance, respectively, in both treat-
ment modalities. A number of studies have shown that
during both low-flux [30–31] and high-flux hemodialysis
[32–33], intradialytic changes in serum Mg and Ca de-
pended mainly on their respective concentration gradi-
ents between dialysate and pretreatment serum levels,
irrespective of the UF volume, blood flow, and dialy-
sis efficiency [30–31]. Thus, in all likelihood, comparable
intradialytic changes in both iCa and sMg, and, conse-
quently, hemodynamic profiles would have been attained
if high-flux dialyzers had been utilized instead of low-flux
dialyzers in the present study. With regard to hemodiafil-
tration (HDF), the much higher UF volumes (up to 40 to
50 L) in comparison to conventional HD may consid-
erably affect the diffusive transport of Ca and Mg. In
addition, the infusion mode (predilution and postdilu-
tion HDF), as well as the variable Ca and Mg concen-
trations of the infusional fluids, may further influence
dialytic Mg and Ca balances. Thus, different HDF pro-
tocols can produce either positive or negative Ca and Mg
fluxes during treatment. Further prospective studies are
needed to investigate the role of simultaneous hypocal-
cemia and hypomagnesemia on cardiovascular stability
in mixed diffusive-convective treatments.
Treatment with a dMg level of 0.25 mmol/L or lower
has been generally used either to prevent and treat Mg
overload in HD patients, or as means to afford giving Mg
containing P binders to control hypercalcemia associated
with the use of calcium salts and vitamin D in the treat-
ment of secondary hyperparathyroidism. In the relevant
studies [31, 34], however, where a low 0.25 mmol/L dMg
was used in conjunction with a low dCa mmol/L, hemo-
dynamic data are not provided for comparison.
The other most important finding of our hemodynamic
study was that during HD with 1.25 mmol/L dCa, the
use of a high dMg of 0.75 mmol/L prevented the BP fall
seen with a low dMg of 0.25 mmol/L. According to our
results, a trivial increase in sMg by 2%, induced by a
0.75 mmol/L dMg, resulted in a less than 6.3% reduc-
tion in mean MAP associated with an analogous mi-
nor decrease in mean TPRI and a constant CI. Actually,
sMg increased only in half of the patients, whereas it de-
creased in the other half of them. It is possible that if
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a higher dMg level had been used, the ensuing higher
degree of hypermagnesemia could have resulted in a
more marked vasodilatory hypotension. However, dMg
concentrations higher than 0.75 mmol/L are not used
in routine HD because of the risk of developing haz-
ardous hypermagnesemia. Conclusively, the use of a high
0.75 mmol/L dMg had no impact on TPR, irrespective of
the concomitant dCa concentration. Interestingly, anal-
ogous changes in TPR were also seen with 0.25 mmol/L
dMg. These findings may help to substantiate the biologic
rationale why increasing the concentration of Mg in the
dialysate during HD with 1.25 mmol/L dCa would im-
prove intradialytic hemodynamics, and thus, blood pres-
sure stability. In the event that the unfavorable effects of
hypomagnesemia were additive to those of hypocalcemia
on cardiac function, an assumption that must be veri-
fied, then the use of 0.75 mmol/L (group III) instead of
0.25 mmol/L dMg (group IV) by circumventing hypomag-
nesemia, or even causing a trivial hypermagnesemia, ap-
parently exerted a beneficial role on cardiac performance.
Thus, with similar nonsignificant changes in TPR induced
by both 0.75 mmol/L and 0.25 mmo/L dMg treatments,
the significantly better preservation of CI seen with
0.75 mmol/L dMg as compared to 0.25 mmol/L dMg
treatment presents a plausible explanation why increas-
ing dMg may prevent IDH during HD with a low dCa of
1.25 mmol/L.
Notwithstanding, because of the opposing effects of Mg
and Ca on the cardiovascular system, the potential role
of Mg on systemic hemodynamics during HD cannot be
definitely judged when iCa is not maintained constant. In
this context, we were justified in opting to use two dif-
ferent dCa levels to overcome this problem. The role of
dMg level on the intradialytic BP, obscured by utilizing a
high 1.75 mmol/L dCa, became evident upon using a low
dCa of 1.25 mmol/L. In the presence of almost identical
iCa and PTH modifications in groups III and IV groups
(Fig. 1), two totally distinct intradialytic BP profiles
emerged (Fig. 2), owing exclusively to the use of two dif-
ferent dMg concentrations in the two groups. In addition,
these data indicated that PTH changes did not impact on
intradialytic BP response, although the prevailing effects
of sMg and iCa on the cardiovascular function could have
masked such an effect. Factors other than dMg and dCa
might possibly have played a role in the BP changes re-
ported in the hemodynamic study. However, differences
among study groups were not found with respect to acid-
base parameters, toxin removal, electrolyte alterations,
and fluid removal. The absence of significant changes in
these factors strengthens our notion that the hemody-
namic modifications observed were dependent solely on
the concurrent changes in serum Mg and Ca. One could
doubt an independent hemodynamic effect of Mg by ar-
guing, for example, that the low Mg effect may have been
mediated by changes in iCa due to an Mg-Ca interaction
lowering iCa during the diffusive therapy. However, the
findings that (1) the intradialytic variations in factors, in-
cluding pH, serum phosphorus, and albumins, that could
potentially affect the ratio of ionized/total Mg (iMg/sMg)
and ionized/total Ca (iCa/sCa) [30] did not differ in the
four treatment groups, (2) the iMg/sMg and iCa/sCa ra-
tios were maintained constant (about 70% and 50%, re-
spectively) with all four different combinations of Mg
and Ca in the dialysate (Table 1), and (3) the intradia-
lytic changes in iMg did not correlate to corresponding
changes in iCa, are against this hypothesis. Therefore,
these results further support a Ca-independent, hemody-
namic role of Mg during HD.
Based on our results, we reasoned that increasing dMg
concentration could prevent or ameliorate the IDH as-
sociated with a low 1.25 mmol/L dCa [10–11, 17]. We
tested this hypothesis in our short-term chronic study
(study B), and it was found to be correct. Overall, BP re-
mained significantly higher with 0.75-mmol/L dMg treat-
ment compared to both 0.5 mmol/L and 0.25 mmol/L
dMg treatments. The superior hemodynamic stability de-
tected with the use of high 0.75 mmol/L dMg was trans-
lated into a significantly reduced incidence of total hy-
potension (symptomatic and asymptomatic) in the high
dMg treatment group as compared to both 0.5 mmol/L
and 0.25 mmol/L dMg treatment groups, as mentioned in
Results. The mean pre- and post-HD values of sMg in
all three treatment groups (Table 3) were similar to the
corresponding values of sMg in previous studies [30, 35],
where treatment was performed with the same dMg con-
centrations, respectively. With regard to the incidence of
hypermagnesemia, sMg slightly increased (less than 1.37
mmol/L) above the upper limit of normal (1.1 mmol/L)
in nine (64%) out of 14 patients in the high dMg group,
and five (36%) in the medium dMg group.
The only available study in which the impact of dMg
level on intradialytic BP was examined [abstract; Rakash
et al, J Am Soc Nephrol 7:1238A, 1996] gave somewhat
contradictory results. In that study, 78 HD patients were
randomly assigned to one of the four treatment groups
with dialysate containing either citrate or bicarbonate
buffer with a low 0.38 mmol/L dMg or a high 0.75 mmol/L
dMg. Patients treated with the high dMg experienced a
larger intradialytic fall in MAP and greater incidence in
intradialytic hypotension than patients treated with the
low dMg (−28 ± 4 mm Hg vs. −16 ± 4 mm Hg and 61.9%
vs. 28.5%, respectively). Similar results were obtained
also with acetate as a buffer. The reasons for this discrep-
ancy are unknown, but differences in the magnitude of
intradialytic changes in sMg in either direction (increase
or decrease), or possibly the variation in other hemodial-
ysis parameters between these two studies, are potential
explanations.
The interesting findings of the present study, if con-
firmed by future investigations, might have clinical
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implications with regard to dialysis tolerance. First, treat-
ment with HD solutions containing 1.25 mmol/L dCa and
low dMg concentrations, shown to be a potential risk
factor for IDH by this pilot study, should be avoided,
especially in IDH-prone patients with impaired cardio-
vascular function. Second, the use of high dMg concen-
trations may be thought as a simple maneuver to prevent
IDH in patients treated with low dCa levels. Accordingly,
patients who manifest hemodynamic instability during
HD with 1.25 mmol/L dCa may benefit upon switching
from a low 0.25 mmol/L or medium 0.5 mmol/L dMg
to a high one of 0.75 mmol/L. This substantiated fa-
vorable hemodynamic effect may play a more critical
role in cardiovascular compromised patients because it
can prevent further deterioration, or even enhance car-
diac performance in these patients when challenged with
adverse hemodynamic conditions. Further studies are
needed to verify this assumption. We opted not to include
patients with severely compromised left cardiac function
in our study to avoid confounding our results. However,
any possible hemodynamic benefits attained during HD
by using high dMg must be weighted against the long-
term consequences of such a treatment [36], including
those related to bone metabolism [37–40]. For exam-
ple, chronic hypermagnesemia, due to its suppressive ef-
fect on PTH secretion, may potentially prevent aggrava-
tion of secondary hyperparathyroidism seen upon using
1.25-mmol/L dCa [41], while suppression of PTH in the
long run could be a risk factor for the development of
adynamic bone disease [37–38].
CONCLUSION
We identified a dialysis solution containing
0.25 mmol/L Mg and 1.25 mmol/L Ca as a signifi-
cant risk factor for developing IDH, and, as such, its use
should be avoided in IDH- prone individuals, especially
cardiac-compromised patients, and we provided strong
evidence that increasing dMg to 0.75 mmol/L could
effectively prevent BP deterioration frequently seen
in patients treated with a low 1.25 mmol/L dCa. Thus,
manipulating dMg levels independently or in concert
with dCa levels might have important implications with
regard to dialysis tolerance. For this reason, the potential
role of the dMg on the cardiovascular system during HD
requires further investigation.
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